ropivacaine + midazolam

ropivacaine + midazolam is a combination of a long-acting amide-type local anesthetic and a benzodiazepine adjuvant being investigated for its efficacy in postoperative pain management. Ropivacaine acts by blocking voltage-gated sodium channels, which inhibits the generation and conduction of nerve impulses, providing regional anesthesia. Midazolam, while primarily used for sedation, is employed in this context as an analgesic adjuvant; when administered peripherally or neuraxially, it is thought to interact with GABA-A receptors to modulate pain signaling and potentially provide a synergistic analgesic effect. This specific combination is being evaluated by Aga Khan University for subcutaneous wound infiltration in patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) to enhance the quality and duration of postoperative analgesia.

Other names

ropivacaine and midazolam